A drug for heart conditions improves efficacy of melanoma therapies

Source: News Medical Life Science, August 2023

A collaborative study undertaken by the Navarrabiomed Biomedical Research Center (Pamplona, ??Navarre), the Institute of Neurosciences CSIC-UMH (Sant Joan d’Alacant, Valencian Community) and IRB Barcelona (Barcelona, ??Catalonia) shows that the administration of ranolazine, a drug currently used to treat heart conditions, improves the efficacy of current therapies for melanoma, in mouse models of this disease.

The journal Nature Metabolism has published the results of the study, which offers an alternative therapeutic approach to treat melanoma, the most deadly type of skin cancer, which affects 16.3 women and 14.6 men per 100,000 inhabitants in Spain.

The development of future clinical trials to validate and confirm the action of ranolazine in cancer patients will be facilitated by the fact that it has already been approved for use in humans and is being administered in clinical practice to treat chronic angina.

READ THE ORIGINAL FULL ARTICLE

Menu